New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer
Study
Phase 3, randomized, double-blind, international trial
|
Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
|
Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281)
|
Efficacy
mOS:23.0 m vs 16.1 months (HR:0.73, P=0.01) in CPS10 subgroup
|
mOS:17.6 m vs 16 months (HR:0.86, P=0.11) in CPS1 subgroup
|
ORR:52.7% vs 40.8 in CPS10 subgroup
|
Safety
Any grade AEs: 96.3 vs 95% (anemia: 49.1% vs 45.9%; neutropenia 41.1% vs 38.1%; nausea 39.3% vs 41.3%)
|
Grade ≥3 AEs 68.1% vs 66.9%
|
Treatment related death: 2 patients and no
|
Immune-mediated adverse events 26.5% vs 6.4%
|
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
